Population variation in VKORC1 haplotype structure [3]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 2, 2006, Pages 473-474

  Marsh, Sharon ^a   King, C R ^a   Porsche Sorbet, R M ^a   Scott Horton, T J ^a   Eby, C S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; MENADIONE EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; OXIDOREDUCTASE; UNCLASSIFIED DRUG; WARFARIN; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG PROTEIN BINDING; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LETTER; MAINTENANCE DRUG DOSE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; ALLELE; GENETICS; PHARMACOGENETICS; RACE;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CONTINENTAL POPULATION GROUPS; GENE FREQUENCY; HAPLOTYPES; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 33645563532     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01759.x     Document Type: Letter

References (7)

1. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
2. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
3. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
4. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
5. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103: 2630-5.
6. Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 687-91.
7. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005; 39: 1008-12.